# NHS

# Bassetlaw Doncaster Clinical Commissioning Group Clinical Commissioning Group Doncaster & Bassetlaw Area Prescribing Committee June 2016 V1.1

# Aviptadil/phentolamine mesilate 25 micrograms / 2 mg solution for injection (Invicorp)

# **TLS Recommendation:**

- Amber-G
- Non-Formulary
- Acquisition costs whilst the basic acquisition cost of this preparation is similar to that of alprostadil injection there is a further unseen cost to the NHS. The unusual distribution of Invicorp, from the manufacturer, is via a non-standard mechanism leading to Community Pharmacy potentially obtaining it via a route that excludes the usual wholesaler processes. This can lead to an additional carriage charge being passed on to Community Pharmacy, which can then be reclaimed. This on-cost charge is not charged directly to the primary care prescribing budget but is however paid for by the NHS.

## Patient selection:

- Patients who have failed to respond to oral therapies
- Patients for whom oral therapy is contraindicated

## Initiation:

- Leger Clinic/Specialist only
- Informed consent is obtained and training is provided to the patient and/or partner

## Follow-up:

- No requirement for a 2<sup>nd</sup> appointment with the Specialist
- Patient will be discharged from clinic
- Leger Clinic will write to the GP informing of treatment being initiated and request the GP to continue the prescription.
- Prescribing should be in line with SLS legislation regarding availability of the prescription on NHS FP10 or as a private prescription.

## Monitoring

• No requirement for either biochemical or physical monitoring

## Side-effects/Risks

- As with all medication for ED there is a small risk of priapism developing.
- Patients are counselled on this at the Leger Clinic and advised that for continuation of priapism longer than 4hours duration patients should seek medical advice via Accident & Emergency. The patient is informed they should not seek advice from their GP on this side-effect as the GP is unable to manage this condition.

http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1437715220891.pdf http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1437715220674.pdf